At the Saturday, Oct. 22 session, ‘Basic Science: Correlates of protection, immune response and the host-microbe interaction,’ of the IDWeek 2022 infectious disease conference, moderator Luiz Bermudez, professor at Oregon State University, introduced the latest advances to prevent infections with Treponema pallidum during neurosyphilis (NS), Staphylococcus aureus and osteomyelitis, and Mycobacterium tuberculosis during influenza.
Standigm Inc. has identified new phenylaminopyrimidine leucine-rich repeat kinase 2 (LRRK2; Dardarin) (G2019S mutant) inhibitors reported to be useful for the treatment neurodegeneration, among other disorders.
Neurocrine Biosciences Inc. has described new vesicular monoamine transporter 2 (VMAT2) inhibitors reported to be useful for the treatment of neurological and psychiatric disorders, among others.
Eli Lilly and Co. has synthesized new glucocorticoid receptor (GR) agonists reported to be useful for the treatment of atopic dermatitis and rheumatoid arthritis.
Chiesi Farmaceutici SpA has synthesized new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Vicore Pharma AB has divulged new angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of rheumatoid arthritis, diabetic nephropathy, pulmonary arterial hypertension, myocardial infarction, pneumonia viral, sarcoidosis, idiopathic pulmonary fibrosis and systemic scleroderma (systemic sclerosis), among other disorders.
Carcinoembryonic antigen (CEA) is an antigen that is overexpressed in colorectal cancers and is considered a suitable target for its treatment. Uppsala University discussed research in the development of the lutetium-177-radiolabeled anti-CEA hT84.66-M5A monoclonal antibody (MAb) 177Lu-DOTA-M5A for the treatment of colorectal cancers and its combination studies with the HSP90 inhibitor onalespib.
At the recent EANM meeting, Point Biopharma Global Inc. presented preclinical details on the development of 177Lu-PNT2001 and 225Ac-PNT2001 for the treatment of prostate cancer.
The suboptimal metabolic stability of radiolabeled gastrin-releasing peptide receptor (GRPR) antagonists has been a hindering factor of these promising theranostic candidates for prostate cancer. Uppsala University researchers have recently reported the development of [111In]DOTAGA-PEG-2-SAR11-RM-26, after replacement of Gly11 by Sar11 in the peptidic chain.
RSS
